NJ-LTIMINDTREE
4.3.2024 14:16:28 CET | Business Wire | Press release
Fosfor, a product division of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, at its Foton 2024 event, announced the launch of the Fosfor Decision Cloud (FDC). The FDC is a connected fabric that helps companies organize data to build automated, modular, trustworthy data transformation pipelines, build and deploy impactful AI applications, and harness the power of AI to make better business decisions, faster.
Currently companies need to create their own collection of disconnected point solutions to facilitate the transformation of data into business insights. The Decision Cloud represents the next step in the evolution of formerly disconnected data and AI investments into a modern decision stack that augments the data-to-decisions journey using three new innovations:
- Fosfor AI: The GenAI-powered assistant that helps with frequent tasks across the data-to-decisions journey such as constructing data pipelines, generating ML model code, constructing natural language prompts, and curating data stories. Fosfor AI radically increases productivity for virtually any user persona, thereby reducing time-to-insights and accelerating the realization of business outcomes.
- Fosfor Semantic: The knowledge graph used by all FDC capabilities to organize and maintain the integrity of data, define data relationships, and enable the application of advanced analytics to the data. Because Fosfor Semantic is used to facilitate everything from data integration to AI algorithm development to insight generation, it vastly accelerates all steps of the data-to-decisions journey.
- Fosfor UX: The design system through which all capabilities are accessed using consistent navigational elements and constructs, curated for specific personas based on their commonly used workflows and goals. Fosfor UX flattens the learning curve and simplifies collaboration across various personas, allowing all users to adapt more quickly to the FDC platform.
The FDC is supported by a robust partner ecosystem anchored by Snowflake, Fivetran, Amazon Web Services, Microsoft Azure, the Google Cloud Platform, and GoldenSource. Snowflake, the Data Cloud company, and Fivetran are FDC launch partners.
“The Decision Cloud marks a major milestone in the evolution of Fosfor and is a major breakthrough in the way businesses can develop and deploy AI to achieve business value,” said Debasis Satpathy, Chief Business Officer, Fosfor. “To elevate the impact of business outcomes, the Decision Cloud brings all the required capabilities onto a single platform, along with powerful insight tools, to support every persona involved in an accelerated data-to-decisions journey. We are excited about the impact the FDC is going to have on the business effectiveness of AI.”
"Organizations across industries continue to struggle with the fragmentation of applications and tools,” said Tarik Dwiek, Head of Technology Alliances, Snowflake. “With the Fosfor Decision Cloud seamlessly integrated into Snowflake, customers can now tap into a single experience to fully democratize their data and fuel their data-driven decision making.”
“Fivetran is pleased to be Fosfor’s launch partner for automated data movement,” said Scott Jones, Chief Revenue Officer, Fivetran. “Providing the foundational capability to integrate with virtually any data source to cost-effectively bring business data into cloud warehouses where the Decision Cloud can then transform it into insights and business value. Using our library of 400+ connectors, Decision Cloud users can focus on building outcome-targeted data products that accelerate their insights journey. We look forward to working together with Fosfor to define the modern decision stack and create transformational outcomes for our customers.”
Learn more about the Fosfor Decision Cloud at www.fosfor.com.
About Fosfor
The Fosfor Decision Cloud is a connected fabric that unifies and amplifies the value promised by the modern data ecosystem, which is made up of infrastructure, data, and application clouds. Fosfor enables organizations to effectively curate data, generate impactful insights, and formulate effective decisions to deliver the long-sought promise of data and AI: optimal business outcomes. Fosfor is part of LTIMindtree, a global technology consulting and digital solutions company. For more information, visit www.fosfor.com.
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 82,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304342757/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom